January 23, 2023 02:48 PM EST
Pharma
FDA+
Marketing

Ad­vo­ca­cy group ac­cus­es No­vo Nordisk of vi­o­lat­ing FDA's 'fair bal­ance' ad­ver­tis­ing rules

Nicole DeFeudis

Editor

A non­prof­it ad­vo­ca­cy group has filed a com­plaint with the FDA ac­cus­ing No­vo Nordisk of lin­ing up pro­mo­tion­al ma­te­r­i­al for its weight loss drug We­govy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times